Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only the signature page and cover-page references.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only the signature page and cover-page references
- No earnings figures or operating results included in the provided Item 2.02 text
Item EX-99.1 · Exhibit EX-99.1
- Second-quarter 2026 results scheduled for August 4, 2026, after market close
- CEO Jack Khattar and CFO Tim Dec hosting investor conference call at 4:30 p.m. ET
- Event provides upcoming readout on CNS product performance, profitability, pipeline progress, and corporate strategy
- Webcast replay available on Supernus’ Investor Relations website for 60 days
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.